Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
RBC Capital starts Breedon at 'outperform'
(Sharecast News) - RBC Capital Markets initiated coverage on construction materials group Breedon on Tuesday with an 'outperform' rating and 575p price target. "Breedon quickly assembled a market leading position in the UK heavy building materials sector," it said.
"Mission accomplished, and in a nod to The Matrix, it is deciding its next move, take the blue pill and become a cash cow or take the red pill and seek transformational growth."
RBC said the value of neither pill is reflected in the current price of the shares, which therefore offers an attractive entry point.
RBC said Breedon's acquisition strategy has been so successful and the barriers to entry it has constructed are so high that the competition authorities are unlikely to allow it to make further transformational acquisitions in the UK or Ireland.
"It could now focus on generating cash and returning cash to shareholders," it said.
"If Breedon takes the 'Blue pill' we believe the dividend per share could be more than doubled as the EBIT margin reaches the higher end of the 12-15% target range and with fewer cashflow calls it could increase the payout ratio from 40% to 60%," the bank said.
"On this basis the FY2025E price-to-earnings ratio falls to 7.6x and the dividend yield rises to 7.9%.
"Take the red pill for growth Breedon has successfully built two commanding platforms - one in Great Britain and the other in the Republic of Ireland, but as they say, good things come in threes."
RBC said that if Breedon takes the 'Red pill' it will seek to replicate its existing successes and build a third platform.
"It has done its research, it knows what taking the red pill means (expanding into the US), but the outcome is more uncertain," the bank said.
"In the note we assume that Breedon has an initial war chest of £400m, which could add circa £40m of EBITDA (+16%,) but this is just a first step in a new journey. If, over the long run, any US EBITDA grew to match the £250m of the current group, based on current peer group multiples, it creates a US business worth £4bn."
RBC said the red pill and the blue pill options offer attractions for different investor bases, blue for income, red for growth and the value of the shares have been treading water as investors wait for Breedon to choose which pill to swallow and which investors to attract.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.